Work on a microfluidic bioreactor for increased active retrovirus output was spotlighted in The January 2008 issue of the Chemical Biology supplement of the Royal Society of Chemistry. In this study, a team led by Professor Martin Yarmush describes a novel microdevice for the continuous production of retroviral vectors in a commonly available packaging cell line. This microdevice platform for virus production enables a high degree of control over environmental conditions, a capability that is critical for optimizing production of retrovirus and other viral vectors for gene therapy applications. The full article describing this work is published in Lab-on-a-Chip 2008, 8: 75-80.